SELECT PUBLICATIONS

Dhanda R et al. A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. Proc ASCO 2006;Abstract 4534.

Eisen T et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. Proc ASCO 2006;Abstract 4524.

Escudier B et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc ASCO 2005;Abstract 4510.

Gollob J et al. Phase II trial of sorafenib plus interferon-alpha 2b (IFN-2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC). Proc ASCO 2006;Abstract 4538.

Ratain MJ et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505- 12. Abstract

Ryan CW et al. Sorafenib plus interferon-2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. Proc ASCO 2006;Abstract 4525.

Teh BT et al. Gene expression profiling identifies two distinct papillary renal cell carcinoma (RCC) subgroups of contrasting prognosis. Proc ASCO 2006;Abstract 4503.

Thomas GV et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12(1):122-7. Abstract

 

 

 

 

 

 

 

 

 

Home

Editor’s Note:
Renal cell fireworks

Interviews
Nicholas J Vogelzang, MD
- Select publications

Ronald M Bukowski, MD
- Select publications

Janice P Dutcher, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office